Abstract:Covering 2010–April 2024 There have been tremendous new discoveries and developments since 2010 in anticancer research based on marine cyanobacteria. Marine cyanobacteria are prolific sources of anticancer natural products, including the tubulin agents dolastatins 10 and 15 which were originally isolated from a mollusk that feeds on cyanobacteria. Decades of research have culminated in the approval of six antibody-drug conjugates (ADCs) and many ongoing clinical trials. Antibody conjugation has been enabling for several natural products, particularly cyanobacterial cytotoxins. Targeting tubulin dynamics has been a major strategy, leading to the discovery of the gatorbulin scaffold, acting on a new pharmacological site. Cyanobacterial compounds with different mechanisms of action (MOA), targeting novel or validated targets in a range of organelles, also show promise as anticancer agents. Important advances include the development of compounds with novel MOA, including apratoxin and coibamide A analogues, modulating cotranslational translocation at the level of Sec61 in the endoplasmic reticulum, largazole and santacruzamate A targeting class I histone deacetylases, and proteasome inhibitors based on carmaphycins, resembling the approved drug carfilzomib. The pipeline extends with SERCA inhibitors, mitochondrial cytotoxins and membrane-targeting agents, which have not yet advanced clinically since the biology is less understood and selectivity concerns remain to be addressed. In addition, efforts have also focused on the identification of chemosensitizing and antimetastatic agents. The review covers the state of current knowledge of marine cyanobacteria as anticancer agents with a focus on the mechanism, target identification and potential for drug development. We highlight the importance of solving the supply problem through chemical synthesis as well as illuminating the biological activity and in-depth mechanistic studies to increase the value of cyanobacterial natural products to catalyze their development.

An update on the development on tubulin inhibitors for the treatment of solid tumors

A review of research progress of antitumor drugs based on tubulin targets

A recent antitumor story of podophyllotoxin derivatives targeting tubulin: an update (2017-2022)

Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy

Indole derivatives as tubulin polymerization inhibitors for the development of promising anticancer agents

The Potential Role of Tubeimosides in Cancer Prevention and Treatment

Drugs that target dynamic microtubules: A new molecular perspective

A new class of cytotoxic agents targets tubulin and disrupts microtubule dynamics

Microtubules as a target for anticancer drugs

Tubulin degradation: Principles, agents, and applications

Tubulin/HDAC dual-target inhibitors: Insights from design strategies, SARs, and therapeutic potential

Development of a novel class of tubulin inhibitors with promising anticancer activities.

Synthesis and biological evaluation of novel indole derivatives containing sulfonamide scaffold as potential tubulin inhibitor

A Novel Microtubule Inhibitor Overcomes Multidrug Resistance in Tumors.

Indole-based, Antiproliferative Agents Targeting Tubulin Polymerization.

Design, Synthesis and Characterization of Potent Microtubule Inhibitors with Dual Anti-Proliferative and Anti-Angiogenic Activities

Progress in the discovery and development of anticancer agents from marine cyanobacteria

Microtubule dynamics in cancer metastasis: Harnessing the underappreciated potential for therapeutic interventions

In Silico Exploration of Novel Tubulin Inhibitors: A Combination of Docking and Molecular Dynamics Simulations, Pharmacophore Modeling, and Virtual Screening

Microtubule-Binding Natural Products for Cancer Therapy

Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy